Abstract
The Pulmonary-Allergy Drugs Advisory Committee (PADAC) evaluates the safety and efficacy of new drugs used in the treatment of pulmonary, allergic, and immunologic diseases.1 Previous studies have shown that positive recommendations from advisory committees are associated with drug approval by the Food and Drug Administration (FDA).2 Our previous studies also showed that speakers with financial conflicts of interest (FCOI) were more likely to speak positively about the drug in question.3,4 Our study of the Bone, Reproductive, and Urologic Drugs Advisory Committee also showed that a drug that was rejected had an increase of 233% in the number of public speakers when the drug was resubmitted.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
